12
Meeting Programme 7 th Annual EANS Vascular Section Meeting 7 - 8 September 2020 Meeting Chairman: Andreas Gruber (Austria)
Meeting Programme
7th Annual EANSVascular Section Meeting
7 - 8 September 2020
Meeting Chairman: Andreas Gruber (Austria)
SCIENTIFICPROGRAMME7thANNUALEANSVASCULARSECTIONMEETING7-8SEPTEMBER2020MeetingChairman:AndreasGruber(Austria)ScientificCommittee:AndreasGruber(Austria)MikaNiemelä(Finland)PeterVajkoczy(Germany)AndreasRaabe(Switzerland)JeroenBoogaarts(TheNetherlands)
DearColleagues,Welcometothe7thAnnualEANSVascularSection,thistime,forthefirsttime,conductedvirtuallyinviewofthecurrentCovid-19pandemicthatcontinuestogripourcountriesinasharedhealthchallenge.Whilewelookforwardtorestrictionsbeingliftedandareturntomeetingphysicallyinfutureyears,letushopeatleastthat2020willprovidealastingreminderandlegacythatwemakegreaterprogressinhealthwhencollaboratingtogetheracrossborders,andpromotingfastexchangeofknowledge,innovationandpractice.That,afterall,isthespiritthatunderpinsourownVascularSectionMeeting,andlongmayitbeso.ThevirtualproductionofthemeetingalsocreatesanunexpectedbenefitinthesensethatwecanopenparticipationtomanymorecolleaguesthanmightotherwisehavebeenpossibleandIhopeyoucanallfindbenefitfromthisviathevirtualnetworkingopportunitiesprovided.IwanttocommenttooonthesenseofgratificationIhavefoundindevelopingtheprogrammeofthisyear’smeetingtobeabletodeepenourclosecollaborativerelationshipwiththeEuropeanSocietyofMinimallyInvasiveNeurologicalTherapy(ESMINT)byhostingajointsession.ThespiritofmultidisciplinarycooperationisalwaysenergisingandIencourageyoualltoenjoywhatIexpecttobeahighlightoftheAnnualMeeting.Sogetyourselfinacomfortablespace,turnupthevolume,turnofftheemailsanddistractions.Wewon’tletCovidstopusfromlearning,exchanging,improving,networkinganddeveloping!AndreasGruberMeetingChairman
Monday7THSEPTEMBER2020
08.45–08.55WelcomeandIntroductionbyJeroenBoogaarts(TheNetherlands)
08.55–09.10 Covid-19andNewYorkDavidLanger(USA)
09.10–11.05 Session1:Aneurysm(clinical)Chairman:Boogaarts(TheNetherlands)
09.10–09.18 Evaluationofuseofmultimodalintraoperativemonitoringduringsupratentorialaneurysmsurgery.Acomparativestudy
LopezOjeda(Spain)
09.18–09.26 Managementofaneurysmalsubarachnoidhaemorrhage17yearsaftertheISATtrial:asurveyofcurrentpracticeintheUKandIreland
Iorga(UnitedKingdom)
09.26–09.34 FocusedsylvianfissureopeningapproachforthetreatmentofunrupturedMCAaneurysms:aretrospectivecomparativestudy
DiBonaventura(Italy)
09.34–09.42 Treatmentstrategyfordistalposteriorinferiorcerebellarartery(PICA)aneurysms:ourinstitutionalseriesandsystematicreview
DiBonaventura(Italy)
09.42–09.50 RetrospectiveapplicationofUIATSscoretoamulticentercohortofrupturedintracranialaneurysms:howitwouldhaveorientedthetreatmentchoices?
Stumpo(Italy)
09.50–09.58 Retrospectiveapplicationofriskscorestorupturedintracranialaneurysms:wouldtheyhavepredictedtheriskofbleeding?
Stumpo(Italy)09.58–10.20Q&Aandgeneraldiscussion
10.20–10.30 Coffeebreak
10.30–10.38 RoutineuseofintraoperativeCTangiographyduringelectiveclipocclusionofcerebralaneurysmsimprovescompleteaneurysmobliterationrates
Schwarting(Germany)
10.38–10.46 Comparisonofpolycystickidneydiseasepatientsamong904sporadicpatientswith
intracranialaneurysmsfromthe@neurISTdatabaseandthereviewoftheliteratureofPKD-patients Haemmerli(Switzerland)
10.46–10.54 Surgicaltreatmentofunrupturedmiddlecerebralarterybifurcationaneurysms:long-
termretrospectivesinglecenterstudy Gmeiner(Austria)10.54–11.10Q&Aandgeneraldiscussion11.10–11.20CoffeeBreak
11.20–12.00 Session2:Aneurysms(ResearchandExperimental) Chairman:vanderZwan(TheNetherlands)11.20–11.28 AspirintreatmentpreventsinflammationinexperimentalbifurcationaneurysmswithdifferentwallconditionsinNewZealandWhiterabbits. Wanderer(Switzerland)11.28–11.36 ComparisonofAneurysmPatencyandMuralInflammationinanArterialRabbitSidewall
andBifurcationAneurysmModelunderConsiderationofDifferentWallCondition Grüter(Switzerland)
11.36–11.44 4Dneurosurgicalsimulatorfortraininganeurysmmicrosurgery
Bervini(Switzerland)11.44–12.00Q&Aandgeneraldiscussion12.00–12.30 Lunch12.30–13.35 Session3:Bypass Chairman:Vajkoczy(Germany)12.30–12.38 Trendsandfashioninresearchofcerebralrevascularization:asystematicreviewofthebypassliterature
Grüter(Switzerland)
12.38–12.46 Vesselocclusionpatterns,clinicalpresentationandoutcomeofextracranialtointracranialbypasssurgeryafterCOSS
Wessels(Germany)
12.46–12.54 Hemodynamicevaluationofpatientswithcarotiddiseaseandimpactofintra-andextracranialrevascularizationprocedures Sebök(Switzerland)
12.54–13.02TheZurichflowchartforSTA-MCAbypassindicationinpatientswithacutestrokebyIC
and/orM1occlusionSebök(Switzerland)
13.02–13.10ImpactofbloodpressurechangesincerebralbloodperfusionofpatientswithischemicmoyamoyadiseaseevaluatedbySPECT
Andrade(Germany) 13.10–13.18 Safetyandfeasibilityoftrans-cranioplastyultrasoundtoallowforpatencyassessmentinthesettingofextracranial-intracranial(EC-IC)bypasssurgery Burkhardt(USA)13.18–13.35Q&Aandgeneraldiscussion13.35–13.45CoffeeBreak13.45–15.35 Session4:Subarachnoidhaemorrhage(SAH) Chairman:Schirmer(USA)13.45–13.53 TheroleofSartansinthetreatmentofstrokeandsubarachnoidhaemorrhage:Asystematicreviewofpreclinicalandclinicalstudies Wanderer(Switzerland)
13.53–14.01 Invasiveneuromonitoringwithanextendeddefinitionofdelayedcerebralischemiaisassociatedwithimprovedoutcomeafterpoor-gradesubarachnoid
haemorrhage.Veldeman(Germany)
14.01–14.09 Procalcitonininthecontextofdelayedcerebralischemiaafteraneurysmalsubarachnoidhaemorrhage
Veldeman(Germany)
14.09–14.17TheHeart-BrainAxisInExperimentalSubarachnoidHemorrhageXu(Germany)
14.17–14.25TheNeuropsychologicalAssessmentBattery(NAB)isavaluabletoolforevaluating
neuropsychologicaloutcomeafteraneurysmaticsubarachnoidhaemorrhageWalter(Germany)
14.25–14.40Q&Aandgeneraldiscussion14.40–14.50 Coffeebreak
14.50–14.58 StereotacticCatheterVentriculocisternostomyandCisternalLavageReducesDelayed
InfarctionandImprovesOutcomeinPatientswithAneurysmalSubarachnoidHemorrhage Scheiwe(Germany)
14.58–15.06 EvolutionofaSAHcase-fatalitybetween1980and2019:asystematicreview
Mahlamäki(Finland)
15.06–15.14 Burdenofaneurysmalsubarachnoidhemorrhageinmiddle-agedpeopleRautalin(Finland)
15.14–15.22Impactofthrombocytetransfusiononrebleedrateandclinicaloutcomeinpatientswith
aneurysmalsubarachnoidhemorrhagewithprehemorrhageantiplateletuseSebök(Switzerland)
15.22–15.35Q&Aandgeneraldiscussion15.35–15.45 Coffeebreak
15.45–17.00 AmericanperspectivesChairman:Schirmer(USA)15.45–15.53AI-basedstrokepreventionforneurosurgeon
Schirmer(USA)15.53–16.01MoyamoyaSyndromeintheBluegrass:ClinicalVariantsandaPotentialModeloftheDisease
Fraser(USA)16.01–16.09Evolvingrevascularization-novelsurgicalandcombinedbypassstrategies
Russin(USA)
16.09–16.17MMAemboforCSDHAlbuquerque(USA)
16.17–16.25AdvancesinminimallyinvasiveICHevacuationKellner(USA)
16.25–16.33Neuroendovascularroboticsfeasibilityandearlyexperience,
Jabbour(USA)16.33–17.00Q&AandgeneraldiscussionENDOFDAYONE
Tuesday8THSEPTEMBER2020
09.00–09.55 Session5:AVMChairman:Raabe
09.00–09.08 SystematicReviewofBrainArteriovenousMalformationGradingSystemsEvaluatingMicrosurgicalTreatmentRecommendation
Grüter(Switzerland)
09.08–09.16 Long-termOutcomesandMultimodalityTreatmentofaSurgicalSeriesofHighGradeArteriovenousMalformations:a10-yearsObservationalStudy
Frio(Italy)
09.16–09.24 7-YearsexperiencewithaninterdisciplinaryAVMconference–fromaneurosurgicalperspective Zweckberger(Germany)
09.24–09.32 PropranololinhibitsSDF1α/CXCR4axis:apossibletreatmentmechanismofcerebralcavernousmalformations
Kashefiolasl (Germany)
09.32–09.40 DiffusenessandAgeinAVMs:ConsiderationsonSurgicalTimingCenzato(Italy)
09.40–09.55Q&Aandgeneraldiscussion
09.55–10.05Coffeebreak
10.05–10.50 Session6:TEAChairman:vanderZwan(TheNetherlands)
10.05–10.13 IncompletecircleofWillispredictstheriskforintraoperativechangesinsomatosensoryevokedpotentialsinpatientsundergoingcarotidendarterectomy:aprospectivecohortstudy
Mueller(Switzerland)
10.13–10.21 Managementofpostoperativecarotidintimalflapaftercarotidendarterectomy
Rychen(Switzerland)
10.21–10.29EndarterectomyforSymptomaticInternalCarotidArteryWebHaynes(USA)
10.29–10.37 A10%decreaseincerebraloxymetryafterselectiveinternalcarotidarterycross-clampingasanindicatorofshuntimplantationduringcarotidendarterectomyHejcl(CzechRepublic)10.37–10.50Q&Aandgeneraldiscussion10.50–11.00Coffeebreak11.00–14.20Session7:EANS/ESMINTJointsessionChairman:Gruber(Austria)11.00–11.08 ParasagittalMeningiomasoccludingcompletelytheSuperiorSagittalSinus.Strategyfor
totalremovalandtheeventualroleofvenousrestorationwithautologousvenousgraftbypass
Georgoulis(Greece)
11.08–11.16 RadiologicaloutcomeofintracranialaneurysmstreatedwithWEBrarelychanges:Comparisonofradiologicaloutcomesat6-monthsand24-months
Rautio(Finland)
11.16–11.24 Pulsationasameasureofinstabilityforintracranialaneurysm.Whatcanwemeasure?
Boogaarts(TheNetherlands)
11.24–11.32 Multicenterclinicalandangiographicresultswiththep48flowdiverterstentVandenBergh(Belgium)
11.32–11.40 Neurovascularconflictoftheanteriorvisualpathway–thenewkidontheblock Müther(Germany)
11.40–11.48 eCLIPsexperienceinwide-neckbifurcationaneurysmswithextremelylowdome-to-neck
andaspectsratioSoerensen(Denmark)
11.48–12.10Q&Aandgeneraldiscussion12.10–12.40 Lunchbreak
12.40–12.48 FinnishFlowDiverterStudy:8yearsofexperienceinthetreatmentofacutelyruptured
intracranialaneurysmsAlpay(Finland)
12.48–12.56 pCONUS2andpCONUS2-HPCfortheTreatmentofUnrupturedWideNeckedIntracranialAneurysms:Periprocedural,6-Month,and2-YearMidtermFollow-UpOutcomes
Yeomans&Sastry(UnitedKingdom)
12.56–13.04 Machinelearningalgorithmsusedforthepredictionofchronicshunt-dependenthydrocephalusafteraneurysmalsubarachnoidhemorrhage-preliminarydatafrom509cases
Gollwitzer(Austria)13.04–13.15Q&Aandgeneraldiscussion13.15–13.25 Coffeebreak13.25–13.33 InitialExperience:FlowDiverterswithhydrophilicpolymercoating(p48hpcandp64hpc)
Kemmling(Germany)13.33–13.41 EndovasculartreatmentofintracranialaneurysmsusingWEBembolizationdevice-a
singlecenter6yearsexperienceMiś(Poland)
13.41–13.49 Comparisonofanteriorandposteriorintracranialarterialdissections
Lee(RepublicofKorea)13.49–13.57 Aneasyandfastalgorithmforcostanalysisofin-hospitalcostsofendovascularcoilingandneurosurgicalclippingforunrupturedintracranialaneurysms
Sherif(Austria)
13.57–14.10Q&Aandgeneraldiscussion14.10–14.20 Coffeebreak14.20–14.55 Session8:EANScerebrovasculartrialsupdate14.20–14.40EANScerebrovasculartrialsupdate
Raabe,Fung,Beck,Bervini,Goldberg
14.40–14.55Q&Aandgeneraldiscussion14.55–15.05 Coffeebreak
15.05–16.10AmericanperspectivesChairman:Welch(USA)15.05–15.13 Valueofahybridoperatingroomforcombinedopenandendovascularprocedures
Griessenauer(USA)15.13–15.21 Advancedonmolecularimagingofcerebralaneurysms
Hasan(USA)
15.21–15.29MinimallyInvasiveParafascicularApproachforResectionofRupturedSubcorticalAVMsSinger(USA)15.29–15.37ComparinglowdoseIVheparintreatedSAHpatientsvsSQheparincontrolin556patients
James(USA)
15.37–15.45IVHandeffectonlong-termgaitdisturbanceandurinaryincontinence Prestigiacomo(USA)
15.45–15.53MicronavigationusingARandHUDduringAVMResectionBederson(USA)15.53–16.10Q&Aandgeneraldiscussion16.10–16.20 Break16.20–16.30Closingofthemeeting
Raabe,Gruber,Niemelä
